Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-21-031388
Date:2021-05-06
Issuer: ULTRAGENYX PHARMACEUTICAL INC. (RARE)
Original Submission Date:

Reporting Person:

PARSCHAUER KARAH HERDMAN
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT NOVATO, CA 94949

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-05-06 S 313 d $113.67 29,997 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 represents shares sold to pay required tax withholdings due to the vesting of rsus.
f2 includes 83 shares acquired under the company's 2014 employee stock purchase plan on april 30, 2021.
f3 includes previously reported shares of common stock underlying rsus granted to the reporting person, which are subject to certain vesting conditions.

Elevate your investments